RSS-Feed abonnieren
DOI: 10.1055/s-0043-1767781
A Review of Neurological Symptoms in Long COVID and Clinical Management
![](https://www.thieme-connect.de/media/sin/202302/lookinside/thumbnails/10-1055-s-0043-1767781_20230024-1.jpg)
Abstract
Long COVID is a clinical diagnosis generally referring to the persistence or development of new symptoms, affecting multiple organ systems after SARS-CoV-2 COVID-19 infection. Long COVID is thought to affect ∼20% of people after infection, including all age ranges and severity of infection. Fatigue, postexertional malaise, and respiratory and cardiac symptoms are commonly described. Neurological symptoms such as cognitive changes, sensory disturbances, headaches, and dysautonomia are common as well. The underlying pathophysiology remains unclear but immune dysregulation, autoimmunity, persistent viral reservoirs, and microvascular dysfunction have been implicated. As there are no tests at this time to diagnose long COVID, work-up should be focused on assessing reversible or treatable causes of symptoms. Furthermore, no treatments for long COVID currently exist, and management remains focused on a multimodal approach and symptom management, with many people showing improvement in symptoms over time.
Publikationsverlauf
Artikel online veröffentlicht:
17. April 2023
© 2023. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 World Health Organization. WHO coronavirus (COVID-19) dashboard. Updated July 12, 2022. Accessed July 13, 2022 at: https://covid19.who.int/
- 2 Centers for Disease Control and Prevention. Long COVID or post-COVID conditions. Updated July 11, 2022. Accessed July 13, 2022 at: https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html
- 3 Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. WHO Clinical Case Definition Working Group on Post-COVID-19 Condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis 2022; 22 (04) e102-e107
- 4 Davis HE, Assaf GS, McCorkell L. et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine 2021; 38: 101019
- 5 Cabrera Martimbianco AL, Pacheco RL, Bagattini AM, Riera R. Frequency, signs and symptoms, and criteria adopted for long COVID-19: a systematic review. Int J Clin Pract 2021; 75 (10) e14357
- 6 CDC National Center for Health Statistics. Nearly one in five American adults who have had COVID-19 still have “long COVID.” Updated June 22, 2022. Accessed August 4, 2022 at: https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/20220622.htm
- 7 Antonelli M, Pujol JC, Spector TD, Ourselin S, Steves CJ. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet 2022; 399 (10343): 2263-2264
- 8 Otto SP, Day T, Arino J. et al. The origins and potential future of SARS-CoV-2 variants of concern in the evolving COVID-19 pandemic. Curr Biol 2021; 31 (14) R918-R929
- 9 Graham EL, Clark JR, Orban ZS. et al. Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized Covid-19 “long haulers”. Ann Clin Transl Neurol 2021; 8 (05) 1073-1085
- 10 Moreno-Pérez O, Merino E, Leon-Ramirez JM. et al; COVID19-ALC research group. Post-acute COVID-19 syndrome. Incidence and risk factors: a Mediterranean cohort study. J Infect 2021; 82 (03) 378-383
- 11 Sudre CH, Murray B, Varsavsky T. et al. Attributes and predictors of long COVID. Nat Med 2021; 27 (04) 626-631
- 12 Huang Y, Pinto MD, Borelli JL. et al. COVID symptoms, symptoms clusters, and predictors for becoming a long-hauler: looking for clarity in the haze of the pandemic.
- 13 Booth A, Reed AB, Ponzo S. et al. Population risk factors for severe disease and mortality in COVID-19: a global systematic review and meta-analysis. PLoS One 2021; 16 (03) e0247461
- 14 Li Y, Ashcroft T, Chung A. et al. Risk factors for poor outcomes in hospitalised COVID-19 patients: a systematic review and meta-analysis. J Glob Health 2021; 11: 10001
- 15 Huang C, Huang L, Wang Y. et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 2021; 397 (10270): 220-232
- 16 Maestre-Muñiz MM, Arias Á, Mata-Vázquez E. et al. Long-term outcomes of patients with coronavirus disease 2019 a one year after hospital discharge. J Clin Med 2021; 10 (13) 2945
- 17 Needham DM, Davidson J, Cohen H. et al. Improving long-term outcomes after discharge from intensive care unit: report from a stakeholders' conference. Crit Care Med 2012; 40 (02) 502-509
- 18 Rousseau AF, Minguet P, Colson C. et al. Post-intensive care syndrome after a critical COVID-19: cohort study from a Belgian follow-up clinic. Ann Intensive Care 2021; 11 (01) 118
- 19 Zangrillo A, Belletti A, Palumbo D. et al; COVID-BioB Study Group. One-year multidisciplinary follow-up of patients with COVID-19 requiring invasive mechanical ventilation. J Cardiothorac Vasc Anesth 2022; 36 (05) 1354-1363
- 20 van Kessel SAM, Olde Hartman TC, Lucassen PLBJ, van Jaarsveld CHM. Post-acute and long-COVID-19 symptoms in patients with mild diseases: a systematic review. Fam Pract 2022; 39 (01) 159-167
- 21 Vanichkachorn G, Newcomb R, Cowl CT. et al. Post-COVID-19 syndrome (long haul syndrome): description of a multidisciplinary clinic at Mayo Clinic and characteristics of the initial patient cohort. Mayo Clin Proc 2021; 96 (07) 1782-1791
- 22 Sandler CX, Wyller VBB, Moss-Morris R. et al. Long COVID and post-infective fatigue syndrome: a review. Open Forum Infect Dis 2021; 8 (10) ofab440
- 23 Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, ; Board on the Health of Select Populations, ; Institute of Medicine. Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. Washington, DC: National Academies Press; 2015
- 24 Wong TL, Weitzer DJ. Long COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)-a systemic review and comparison of clinical presentation and symptomatology. Medicina (Kaunas) 2021; 57 (05) 418
- 25 Bateman L, Bested AC, Bonilla HF. et al. Myalgic encephalomyelitis/chronic fatigue syndrome: essentials of diagnosis and management. Mayo Clin Proc 2021; 96 (11) 2861-2878
- 26 Michelen M, Manoharan L, Elkheir N. et al. Characterising long COVID: a living systematic review. BMJ Glob Health 2021; 6 (09) e005427
- 27 Ceban F, Ling S, Lui LMW. et al. Fatigue and cognitive impairment in post-COVID-19 syndrome: a systematic review and meta-analysis. Brain Behav Immun 2022; 101: 93-135
- 28 Becker JH, Lin JJ, Doernberg M. et al. Assessment of cognitive function in patients after COVID-19 infection. JAMA Netw Open 2021; 4 (10) e2130645
- 29 Valdes E, Fuchs B, Morrison C. et al. Demographic and social determinants of cognitive dysfunction following hospitalization for COVID-19. J Neurol Sci 2022; 438: 120146
- 30 Cristillo V, Pilotto A, Cotti Piccinelli S. et al; Neuro Covid Next Study group. Premorbid vulnerability and disease severity impact on Long-COVID cognitive impairment. Aging Clin Exp Res 2022; 34 (01) 257-260
- 31 Liu YH, Wang YR, Wang QH. et al. Post-infection cognitive impairments in a cohort of elderly patients with COVID-19. Mol Neurodegener 2021; 16 (01) 48
- 32 Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry 2021; 8 (05) 416-427
- 33 Wang L, Davis PB, Volkow ND, Berger NA, Kaelber DC, Xu R. Association of COVID-19 with new-onset Alzheimer's disease. J Alzheimers Dis 2022; 89 (02) 411-414
- 34 Larsen NW, Stiles LE, Miglis MG. Preparing for the long-haul: autonomic complications of COVID-19. Auton Neurosci 2021; 235: 102841
- 35 Shouman K, Vanichkachorn G, Cheshire WP. et al. Autonomic dysfunction following COVID-19 infection: an early experience. Clin Auton Res 2021; 31 (03) 385-394
- 36 Barizien N, Le Guen M, Russel S, Touche P, Huang F, Vallée A. Clinical characterization of dysautonomia in long COVID-19 patients. Sci Rep 2021; 11 (01) 14042
- 37 Borges do Nascimento IJ, Cacic N, Abdulazeem HM. et al. Novel coronavirus infection (COVID-19) in humans: a scoping review and meta-analysis. J Clin Med 2020; 9 (04) 941
- 38 Lopez-Leon S, Wegman-Ostrosky T, Perelman C. et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep 2021; 11 (01) 16144
- 39 Diaz-Mitoma F, Vanast WJ, Tyrrell DL. Increased frequency of Epstein-Barr virus excretion in patients with new daily persistent headaches. Lancet 1987; 1 (8530): 411-415
- 40 Martelletti P, Bentivegna E, Spuntarelli V, Luciani M. Long-COVID headache. SN Compr Clin Med 2021; 3 (08) 1704-1706
- 41 Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, ; Board on the Health of Select Populations; Institute of Medicine. Current case definitions and diagnostic criteria, terminology, and symptom constructs and clusters. In: Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. Washington, DC: National Academies Press; 2015
- 42 Silva MTT, Lima MA, Torezani G. et al. Isolated intracranial hypertension associated with COVID-19. Cephalalgia 2020; 40 (13) 1452-1458
- 43 Dakay K, Cooper J, Bloomfield J. et al. Cerebral venous sinus thrombosis in COVID-19 infection: a case series and review of the literature. J Stroke Cerebrovasc Dis 2021; 30 (01) 105434
- 44 Palaiodimou L, Stefanou MI, Katsanos AH. et al. Cerebral venous sinus thrombosis and thrombotic events after vector-based COVID-19 vaccines: a systematic review and meta-analysis. Neurology 2021; 97 (21) e2136-e2147
- 45 Oaklander AL, Mills AJ, Kelley M. et al. Peripheral neuropathy evaluations of patients with prolonged long COVID. Neurol Neuroimmunol Neuroinflamm 2022; 9 (03) e1146
- 46 Abrams RMC, Simpson DM, Navis A, Jette N, Zhou L, Shin SC. Small fiber neuropathy associated with SARS-CoV-2 infection. Muscle Nerve 2022; 65 (04) 440-443
- 47 Raahimi MM, Kane A, Moore CE, Alareed AW. Late onset of Guillain-Barré syndrome following SARS-CoV-2 infection: part of ‘long COVID-19 syndrome’?. BMJ Case Rep 2021; 14 (01) e240178
- 48 Premraj L, Kannapadi NV, Briggs J. et al. Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: a meta-analysis. J Neurol Sci 2022; 434: 120162
- 49 Vindegaard N, Benros ME. COVID-19 pandemic and mental health consequences: systematic review of the current evidence. Brain Behav Immun 2020; 89: 531-542
- 50 Mazza MG, De Lorenzo R, Conte C. et al; COVID-19 BioB Outpatient Clinic Study group. Anxiety and depression in COVID-19 survivors: role of inflammatory and clinical predictors. Brain Behav Immun 2020; 89: 594-600
- 51 Meng X, Deng Y, Dai Z, Meng Z. COVID-19 and anosmia: a review based on up-to-date knowledge. Am J Otolaryngol 2020; 41 (05) 102581
- 52 Hickie I, Davenport T, Wakefield D. et al; Dubbo Infection Outcomes Study Group. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. BMJ 2006; 333 (7568): 575
- 53 Lam MH, Wing YK, Yu MW. et al. Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors: long-term follow-up. Arch Intern Med 2009; 169 (22) 2142-2147
- 54 Sotzny F, Blanco J, Capelli E. et al; European Network on ME/CFS (EUROMENE). Myalgic encephalomyelitis/chronic fatigue syndrome - evidence for an autoimmune disease. Autoimmun Rev 2018; 17 (06) 601-609
- 55 Ryan FJ, Hope CM, Masavuli MG. et al. Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection. BMC Med 2022; 20 (01) 26
- 56 Scherlinger M, Felten R, Gallais F. et al. Refining “long-COVID” by a prospective multimodal evaluation of patients with long-term symptoms attributed to SARS-CoV-2 infection. Infect Dis Ther 2021; 10 (03) 1747-1763
- 57 Robinson-Papp J, Astha V, Nmashie A. et al. Sympathetic function and markers of inflammation in well-controlled HIV. Brain Behav Immun Health 2020; 7: 100112
- 58 Robinson-Papp J, Nmashie A, Pedowitz E. et al. Vagal dysfunction and small intestinal bacterial overgrowth: novel pathways to chronic inflammation in HIV. AIDS 2018; 32 (09) 1147-1156
- 59 Matschke J, Lütgehetmann M, Hagel C. et al. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Lancet Neurol 2020; 19 (11) 919-929
- 60 Thakur KT, Miller EH, Glendinning MD. et al. COVID-19 neuropathology at Columbia University Irving Medical Center/New York Presbyterian Hospital. Brain 2021; 144 (09) 2696-2708
- 61 Douaud G, Lee S, Alfaro-Almagro F. et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature 2022; 604 (7907): 697-707
- 62 Guedj E, Campion JY, Dudouet P. et al. 18F-FDG brain PET hypometabolism in patients with long COVID. Eur J Nucl Med Mol Imaging 2021; 48 (09) 2823-2833
- 63 Fogarty H, Townsend L, Morrin H. et al; Irish COVID-19 Vasculopathy Study (iCVS) investigators. Persistent endotheliopathy in the pathogenesis of long COVID syndrome. J Thromb Haemost 2021; 19 (10) 2546-2553
- 64 Seeßle J, Waterboer T, Hippchen T. et al. Persistent symptoms in adult patients 1 year after coronavirus disease 2019 (COVID-19): a prospective cohort study. Clin Infect Dis 2022; 74 (07) 1191-1198
- 65 Grubb BP. Postural tachycardia syndrome. Circulation 2008; 117 (21) 2814-2817
- 66 Basantsova NY, Starshinova AA, Dori A, Zinchenko YS, Yablonskiy PK, Shoenfeld Y. Small-fiber neuropathy definition, diagnosis, and treatment. Neurol Sci 2019; 40 (07) 1343-1350
- 67 Ohira M, Sano T, Takao M. Clinical features of patients who visited the outpatient clinic for long COVID in Japan. eNeurologicalSci 2022; 28: 100418
- 68 Bungenberg J, Humkamp K, Hohenfeld C. et al. Long COVID-19: objectifying most self-reported neurological symptoms. Ann Clin Transl Neurol 2022; 9 (02) 141-154
- 69 Gottlieb DJ, Punjabi NM. Diagnosis and management of obstructive sleep apnea: a review. JAMA 2020; 323 (14) 1389-1400
- 70 Mekhael M, Lim CH, El Hajjar AH. et al. Studying the effect of long COVID-19 infection on sleep quality using wearable health devices: observational study. J Med Internet Res 2022; 24 (07) e38000
- 71 Balcom EF, Nath A, Power C. Acute and chronic neurological disorders in COVID-19: potential mechanisms of disease. Brain 2021; 144 (12) 3576-3588
- 72 WHO. Living Guidance for Clinical Management of COVID-19. Geneva: WHO; 2021
- 73 Nakanishi N, Liu K, Kawakami D. et al. Post-intensive care syndrome and its new challenges in coronavirus disease 2019 (COVID-19) pandemic: a review of recent advances and perspectives. J Clin Med 2021; 10 (17) 3870
- 74 Centers for Disease Control and Prevention. Assessment for testing: evaluating and caring for patients with post-COVID conditions, interim guidance. Updated June 14, 2021. Accessed September 17, 2022 at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-assessment-testing.html
- 75 Besnier F, Bérubé B, Malo J. et al. Cardiopulmonary rehabilitation in long-COVID-19 patients with persistent breathlessness and fatigue: the COVID-rehab study. Int J Environ Res Public Health 2022; 19 (07) 4133
- 76 Centers for Disease Control and Prevention. Treatment of ME/CFS. Updated January 28, 2021. Accessed September 17, 2022 at: https://www.cdc.gov/me-cfs/treatment/index.html
- 77 Vance H, Maslach A, Stoneman E. et al. Addressing post-COVID symptoms: a guide for primary care physicians. J Am Board Fam Med 2021; 34 (06) 1229-1242
- 78 Olaithe M, Bucks RS, Hillman DR, Eastwood PR. Cognitive deficits in obstructive sleep apnea: insights from a meta-review and comparison with deficits observed in COPD, insomnia, and sleep deprivation. Sleep Med Rev 2018; 38: 39-49
- 79 García A, Angel JD, Borrani J, Ramirez C, Valdez P. Sleep deprivation effects on basic cognitive processes: which components of attention, working memory, and executive functions are more susceptible to the lack of sleep?. Sleep Sci 2021; 14 (02) 107-118
- 80 Ahern E, Semkovska M. Cognitive functioning in the first-episode of major depressive disorder: a systematic review and meta-analysis. Neuropsychology 2017; 31 (01) 52-72
- 81 Schreiber M. Treating patients with long COVID. Monit Psychol 2021;52(05). Accessed September 18, 2022 at: https://www.apa.org/monitor/2021/07/treating-long-covid
- 82 Mtinangi BL, Hainsworth R. Early effects of oral salt on plasma volume, orthostatic tolerance, and baroreceptor sensitivity in patients with syncope. Clin Auton Res 1998; 8 (04) 231-235
- 83 Fu Q, Levine BD. Exercise and non-pharmacological treatment of POTS. Auton Neurosci 2018; 215: 20-27
- 84 Sheldon RS, Grubb II BP, Olshansky B. et al. 2015 heart rhythm society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. Heart Rhythm 2015; 12 (06) e41-e63
- 85 Winker R, Barth A, Bidmon D. et al. Endurance exercise training in orthostatic intolerance: a randomized, controlled trial. Hypertension 2005; 45 (03) 391-398
- 86 Raj SR, Black BK, Biaggioni I. et al. Propranolol decreases tachycardia and improves symptoms in the postural tachycardia syndrome: less is more. Circulation 2009; 120 (09) 725-734
- 87 Raj SR, Black BK, Biaggioni I, Harris PA, Robertson D. Acetylcholinesterase inhibition improves tachycardia in postural tachycardia syndrome. Circulation 2005; 111 (21) 2734-2740
- 88 Taub PR, Zadourian A, Lo HC, Ormiston CK, Golshan S, Hsu JC. Randomized trial of ivabradine in patients with hyperadrenergic postural orthostatic tachycardia syndrome. J Am Coll Cardiol 2021; 77 (07) 861-871
- 89 Finnerup NB, Attal N, Haroutounian S. et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 2015; 14 (02) 162-173
- 90 Robbins MS. Diagnosis and management of headache: a review. JAMA 2021; 325 (18) 1874-1885
- 91 AAN Summary of Evidence-based Guidelines for Clinician. Update: Pharmacologic treatment for episodic migraine prevention in adults. American Academy of Neurology and American Headache Society. 2015. Accessed September 18, 2022 at: https://www.aan.com/Guidelines/home/GuidelineDetail/536
- 92 Yamani N, Olesen J. New daily persistent headache: a systematic review on an enigmatic disorder. J Headache Pain 2019; 20 (01) 80
- 93 O'Kelly B, Vidal L, McHugh T, Woo J, Avramovic G, Lambert JS. Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study. Brain Behav Immun Health 2022; 24: 100485